| Immunoproliferative Disorders |
NCT02670564: ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) |
|
|
| Recruiting | 4 | 1000 | Europe | Pharmacogenomics, DNA analyses, Busulfan plasma level measurements | Swiss Pediatric Oncology Group, ALL SCTped Forum | Acute Lymphoblastic Leukemia | 04/21 | 04/26 | | |
NCT02938741: ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors |
|
|
| Recruiting | 4 | 130 | RoW | Anti-human Thymoglobulin, (r-ATG ）, Placebo | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Lymphoblastic Lymphoma | 12/21 | 12/22 | | |
NCT02449252: Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma |
|
|
| Recruiting | 3 | 120 | RoW | Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone | Wuhan University | Follicular Lymphoma | 10/19 | 10/25 | | |
NCT02449278: The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 120 | RoW | Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone | Wuhan University | Diffuse Large B-cell Lymphoma | 10/19 | 10/25 | | |
NCT02449265: Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 160 | RoW | Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone | Wuhan University | Diffuse Large B-cell Lymphoma | 10/19 | 10/25 | | |
WUCC-NHL02, NCT02438501: Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma |
|
|
| Recruiting | 3 | 166 | RoW | Low-dose involved-field radiotherapy, Involved-field radiotherapy | Di Deng | Recurrent Follicular Lymphoma | 10/19 | 10/25 | | |
| Recruiting | 3 | 226 | RoW | Thalidomide, Thalomid, Observation | Nanfang Hospital of Southern Medical University | Lymphoma, Large B-Cell, Diffuse | 12/19 | 12/23 | | |
NCT02842931: R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis |
|
|
| Recruiting | 3 | 300 | RoW | R-DA-EPOCH-21, R-DA-EPOCH-21 + auto-SCT, R-mNHL-BFM-90, R-mNHL-BFM-90 + auto-SCT | National Research Center for Hematology, Russia, National Research Center for Hematology | Diffuse Large B-Cell Lymphoma | 02/20 | 02/23 | | |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
| Active, not recruiting | 3 | 4420 | Europe | Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) | University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen | Multiple Myeloma | 12/21 | 12/22 | | |
|
|
| Recruiting | 3 | 840 | RoW | Standard Arm, Experimental Arm | Tata Memorial Hospital | NonHodgkin Lymphoma | 11/22 | 06/23 | | |
CAALL-F01, NCT02716233: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents |
|
|
| Recruiting | 3 | 1578 | Europe | pegaspargase 1250 IU/m2 x 2, ONCASPAR 1250 IU/m2 x 2, pegaspargase 2500 IU/m2 x 1, ONCASPAR 2500 IU/m2 x 1 | Assistance Publique - Hôpitaux de Paris, Shire | Acute Lymphoblastic Leukemia | 04/26 | 04/26 | | |
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia |
|
|
| Active, not recruiting | 2/3 | 640 | US, Canada, RoW | Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma | 12/20 | 12/20 | | |
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients |
|
|
| Active, not recruiting | 2 | 140 | Europe | cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2 | Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories | Primary Central Nervous System Lymphoma | 05/16 | 05/26 | | |
NCT02388581: First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL |
|
|
| Recruiting | 2 | 30 | RoW | Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole, Anti-H. pylori Therapy | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Mackay Memorial Hospital, China Medical University Hospital, Taichung Veterans General Hospital, Changhua Christian Hospital, National Cheng-Kung University Hospital, Chang Gung Memorial Hospital, Kaohsiung Medical University | Gastric Diffuse Large B-cell Lymphoma | 12/17 | 12/24 | | |
PTL, NCT02753062: Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 22 | RoW | bendamustine, rituximab, symbenda, mabthera | Asan Medical Center, Cheolwon Suh | Diffuse Large B Cell Lymphoma | 08/18 | 08/23 | | |
| Recruiting | 2 | 135 | Europe | R-DHAP/R-ICE, R-DHAP or R-ICE and BEAM or FEAM | Fondazione Italiana Linfomi ONLUS | Non Hodgkin Lymphoma | 12/18 | 02/23 | | |
NCT02840539: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma |
|
|
| Completed | 2 | 19 | RoW | Bortezomib, Cytarabine, Dexamethasone, Pegteograstim, Protezomib, Cytarabine, Dexamethasone, Neulapeg | Seoul National University Hospital, Consortium for Improving Survival of Lymphoma | Mantle Cell Lymphoma | 03/21 | 12/22 | | |
NCT02339350: Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children |
|
|
| Recruiting | 2 | 110 | RoW | high dose methotrexate, Intrathecal triple chemotherapy | The Korean Society of Pediatric Hematology Oncology | Acute Lymphoblastic Leukemia, Child | 04/23 | 04/23 | | |
| Recruiting | 2 | 34 | RoW | Ibrutinib-RICE, Imbruvica | Singapore General Hospital, Janssen, LP | Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent | 08/23 | 08/23 | | |
NCT02497898: Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma |
|
|
| Not yet recruiting | 2 | 1000 | RoW | Cytokine-induced killer cells (CIK) | The First People's Hospital of Changzhou | Lymphoma, Non-Hodgkin | 07/38 | 07/40 | | |
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma |
|
|
| Active, not recruiting | 1/2 | 56 | US | Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone | Cristina Gasparetto, Celgene | Multiple Myeloma | 12/16 | 01/25 | | |
NCT02259556: CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas |
|
|
| Recruiting | 1/2 | 30 | RoW | CART30, anti-CD30 CAR T cells | Chinese PLA General Hospital | Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | 10/18 | 10/29 | | |
NCT02987244: Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | Chidamide, epidaza, Cyclophosphamide, Epirubicin, Vindesine, Etoposide, Prednisone | Peking Union Medical College Hospital, Chinese PLA General Hospital, Peking University First Hospital, Peking University Third Hospital, Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital | T Cell Non-Hodgkin's Lymphoma | 03/20 | 03/23 | | |
TMI-ASCT, NCT00800059: Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma |
|
|
| Recruiting | 1/2 | 27 | Canada | Total Marrow Irradiation, TMI | Ottawa Hospital Research Institute | Multiple Myeloma | 11/20 | 11/25 | | |
NCT00960050: Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone |
|
|
| Active, not recruiting | 1 | 173 | US | polymorphism analysis, laboratory biomarker analysis, medical chart review, assessment of therapy complications | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Leukemia, Lymphoma, Methemoglobinemia, Nonmalignant Neoplasm | 05/15 | | | |
NCT01999491: A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma |
|
|
| Active, not recruiting | 1 | 39 | US | NC-4016 | M.D. Anderson Cancer Center, NanoCarrier Co., Ltd. | Advanced Cancers, Lymphoma | 11/18 | 11/18 | | |
NCT01250808: Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy |
|
|
| Available | N/A | | RoW | Bortezomib/Dexamethasone/Melphalan | Peking University | Multiple Myeloma | | | | |
| No Longer Available | N/A | | US | Erwinia L-asparaginase, Erwinase | Phoenix Children's Hospital, Fisher Bioservices, Jazz Pharmaceuticals | Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia | | | | |
NCT02055040: Detection of Cardiac Fibrosis in Patients With Lymphoma |
|
|
| | N/A | 77 | US | Cardiac Magnetic Resonance Scan | Dana-Farber Cancer Institute | Lymphoma | 03/14 | | | |
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. |
|
|
| No Longer Available | N/A | | US | Plerixafor, AMD3100, Mozobil | Genzyme, a Sanofi Company | Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma | | | | |
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib |
|
|
| No Longer Available | N/A | | US | Carfilzomib | University of Arkansas, Onyx Therapeutics, Inc. | Multiple Myeloma | 04/15 | 04/15 | | |
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Elotuzumab, BMS-901608 | Sundar Jagannath, Bristol-Myers Squibb | Multiple Myeloma | | | | |
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients |
|
|
| No Longer Available | N/A | | Canada | bortezomib, melphalan, prednisone | Janssen-Ortho Inc., Canada, Ortho Biotech Canada | Multiple Myeloma | | | | |
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Panobinostat | Novartis Pharmaceuticals | Multiple Myeloma | | | | |
NCT02666209: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Ulocuplumab, BMS-936564, Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Decadron | Dana-Farber Cancer Institute, Bristol-Myers Squibb | Multiple Myeloma in Relapse, Multiple Myeloma | | | | |
| Recruiting | N/A | 10 | US | 124I-PU-AD, PET Scan, Blood draws | Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University, Samus Therapeutics, Inc. | Solid Malignancy, Lymphoma, Multiple Myeloma, Alzheimer's Disease | 04/18 | 08/18 | | |
EAP, NCT02197650: Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase |
|
|
| No Longer Available | N/A | | Europe | suspension of erythrocytes encapsulating L-asparaginase, GRASPA®, eryaspase | ERYtech Pharma | Acute Lymphoblastic Leukemia | | | | |
| Recruiting | N/A | 550 | RoW | | Claudio Gustavo Stefanoff, Adriana Alves de Souza Scheliga, Claudete Esteves Nogueira Pinto Klumb, Ricardo de Sá Bigni, Luciana Wernersbach Pinto, Rocio Hassan, Isabele Avila Small, Monik Mariano Pinto, Cecilia Ferreira da Silva | Lymphoma | 12/18 | 12/25 | | |
| Recruiting | N/A | 100 | Europe | | Versailles Hospital | Lymphoblastic Leukemia, Acute | 12/20 | 12/22 | | |
GRAALL-2014/B, NCT02617004: Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults |
|
|
| Recruiting | N/A | 500 | Europe | | Assistance Publique - Hôpitaux de Paris | Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia | 12/20 | 12/25 | | |
| Recruiting | N/A | 2200 | RoW | Radiotherapy:, Vincristine, Etoposide, Prednisone, Doxorubicin, Dacarbazine, Cyclophosphamide | GALIA AVRAHAMI, University of Giessen | Classical Hodgkins Lymphoma in Children and Adolescents. | 12/22 | 12/27 | | |
CoMMpass, NCT01454297: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile |
|
|
| Completed | N/A | 1154 | Europe, Canada, US | | Multiple Myeloma Research Foundation, Translational Genomics Research Institute, Spectrum Health Hospitals, Van Andel Research Institute | Multiple Myeloma | 11/23 | 12/23 | | |
| Recruiting | N/A | 16000 | Europe | Data collection | Institut Paoli-Calmettes | Lymphoma | 01/30 | 12/30 | | |
NCT02869529: Institut Paoli Calmettes Chronic Lymphatic Leukemia Database |
|
|
| Recruiting | N/A | 4200 | Europe | Data collection | Institut Paoli-Calmettes | Leukemia, Lymphocytic, Chronic, B-Cell | 01/30 | 12/30 | | |
NCT02869555: Institut Paoli Calmettes Multiple Myeloma Database |
|
|
| Recruiting | N/A | 5000 | Europe | Data collection | Institut Paoli-Calmettes | Multiple Myeloma | 01/30 | 12/30 | | |